Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.

MLA

Yosipovitch, Gil, et al. “Lebrikizumab Improved Itch and Reduced the Extent of Itch Interference on Sleep in Patients with Moderate-to-Severe Atopic Dermatitis: Two Randomized, Placebo-Controlled, Phase III Trials.” British Journal of Dermatology, vol. 190, no. 2, Feb. 2024, pp. 289–91. EBSCOhost, https://doi.org/10.1093/bjd/ljad435.

APA

Yosipovitch, G., Lio, P. A., Rosmarin, D., Serra-Baldrich, E., Legat, F. J., Casillas, M., Pierce, E., Liu, Z., Sun, L., Elmaraghy, H., & Ständer, S. (2024). Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials. British Journal of Dermatology, 190(2), 289–291. https://doi.org/10.1093/bjd/ljad435

Chicago

Yosipovitch, Gil, Peter A Lio, David Rosmarin, Esther Serra-Baldrich, Franz J Legat, Marta Casillas, Evangeline Pierce, et al. 2024. “Lebrikizumab Improved Itch and Reduced the Extent of Itch Interference on Sleep in Patients with Moderate-to-Severe Atopic Dermatitis: Two Randomized, Placebo-Controlled, Phase III Trials.” British Journal of Dermatology 190 (2): 289–91. doi:10.1093/bjd/ljad435.